Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies

Saved in:
Bibliographic Details
Published inEuropean urology Vol. 83; pp. S758 - S759
Main Authors Kwiatek, M., Gutierrez, M., Harvey, R.D., Sullivan, R.J., Walter, H.S., Faulhaber, N., Jauch-Lembach, J., Kann, L., Lakhani, N.J.
Format Journal Article
LanguageEnglish
Published 01.02.2023
Online AccessGet full text

Cover

More Information
ISSN:0302-2838
DOI:10.1016/S0302-2838(23)00578-X